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pen accessAbstract Introduction: Postoperative urine retention is a common problem faced withmany epidur-
ally administered drugs to relief pain. Morphine was introduced as a potent epidural analgesic, how-
ever; its administration is associated with a high incidence of urine retention. Neostigmine had been
proposedas an epidural analgesic that lacksmajor side effects facedwith intrathecal neostigmine.How-
ever, the effect of the combined use of both drugs upon lower urinary system has not been discussed.
Methods: 100Patients allocated into 4 equal groupswere subjected to inguinal hernia repair under epi-
dural anesthesia. Group I received bupivacaine 10 ml 0.5%, Group II received bupivacaine/morphine
2 mg,Group III received bupivacaine/morphine 2 mg and 5 lg/kg neostigmine andGroup IV received
bupivacaine and 5 lg/kg neostigmine. Incidences of postoperative urine retention and patients who
needed catheterization in each group were recorded. Mean arterial blood pressure, heart rate and inci-
dence of complication (nausea, vomiting, pruritis, hypotension and bradycardia) were recorded. Time
for 1st rescue analgesic drug was recorded.
Results: No single patient experienced urine retention in Group IV. Whereas one patient in both
Groups I and III versus ﬁve patients in Group II suffered from urine retention and required urinaryom (H.A. El Dahab).
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90 H.A. El Dahab et al.catheterization. The hemodynamic parameters were comparable between all groups. Time for 1st res-
cue analgesic drug was prolonged in Group III more than the other groups followed by Groups II, IV
and I, respectively.
Conclusion: Addition of neostigmine to morphine epidurally lessened the incidence of postoperative
urine retention commonly faced when morphine is used alone with local anesthetic and prolonged
the duration of analgesia.
ª 2011 Egyptian Society of Anesthesiologists. Production and hosting by Elsevier B.V.
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Urinary retention after surgery is a common problem with an
incidence ranging from 5% to 70%. The adult urinary bladder
has a capacity of 400–600 ml. When a bladder volume of
150 ml is reached, the ﬁrst urge to void is felt while at a volume
of 300 ml sense of fullness occurs due to activation of the ten-
sion receptors in the bladder wall [1]. Urinary retention in-
creases the rate of urinary tract infections. It is treated by
urethral catheterization that may further increase the incidence
of urinary tract infection [2]. Male gender, increasing age, mul-
tiple sclerosis, spinal lesion, a history of bladder outﬂow prob-
lems or surgeries and postoperative epidural analgesia are
considered risk factors for the development of urinary reten-
tion [3–6]. By acting on the sacral and lumbar nerve ﬁbers, epi-
durally administered local anesthetics block the transmission
of afferent and efferent nervous impulses from the bladder
increasing the incidence of postoperative urine retention
(POUR). The use of long-acting local anesthetics is associated
with a higher incidence of POUR [7–10]. Epidural morphine
decreases detrusor strength within 5–15 min reaching its max-
imum effects within 30–120 min and lasting 10–15 h [11,12].
Thus the addition of opioids to epidural local anesthetics in-
creases the risk of POUR [13]. Neostigmine is a reversible cho-
linesterase inhibitor. It was used for intrathecal injection as it
produces dose dependant analgesia without respiratory depres-
sion or hypotension and potentiates the analgesic effects of
both narcotic and local anesthetic. Unfortunately, severe gas-
trointestinal side effects (nausea, vomiting and diarrhea) oc-
curred limiting its routine use. These side effects are thought
to be due to rostral spread. However, epidural neostigmine
was investigated and found to produce postoperative analgesia
for several hours and lack these side effects [14–16]. Being a
muscarinic agonist, neostigmine causes an increase in intraves-
ical pressure, leading to hyperactive detrusor contractions
[17,18] and parenteral neostigmine was used in reversing post-
operative non-obstructive urinary retention [19] and morphine
induced retention [20]. While anticholinergic drugs, such as
atropine, block detrusor contractions and cause bladder hypo-
tonia resulting in urinary retention [6,21].
This study was designed to assess the value of using epidu-
ral neostigmine on bladder function and whether mixing
neostigmine with morphine will lessen the incidence of postop-
erative urine retention commonly faced with epidural mor-
phine or not? Furthermore, to follow-up the analgesic
properties as well as the possible side effects.2. Materials and methods
After approval of the ethical and scientiﬁc research commit-
tee of the El-Kasr Aini hospital, 100 patients were enrolled inthis prospective double blinded study to undergo inguinal
hernia repair under epidural anesthesia in the period between
January 2008 and December 2009. Male patients aged 20–
50 years old with ASA class I, II were included in the study.
Patients suffering from bronchial asthma, symptoms of blad-
der outlet obstruction, history of lower urinary tract surgery
(prostate or urethra) and history of neurological disorder
(stroke, poliomyelitis, cerebral palsy, multiple sclerosis, spinal
lesions, diabetic and alcoholic neuropathy) were excluded
from the study aiming to avoid any factor that might in-
crease the risk of development of POUR. Also patients hav-
ing any contraindication to regional anesthesia (patient’s
refusal, patients on anticoagulants, skin infection at the site
of injection, severe aortic stenosis, severe mitral stenosis,
spine anomalies and deformities) and those experiencing acci-
dental dural puncture during the procedure were excluded
from the study.
History taking, the international prostate symptom score
(IPSS), ﬂowmetry test and ultrasound (U/S) assessment of
the lower urinary system, especially post void residual urine
estimation were done for all patients as a routine by the urol-
ogist. Any patient with IPSS more than 7 or maximum ﬂow
rate (Qmax) less than 15 ml/s were excluded from the study.
Preoperatively, all patients were instructed how to respond
to visual analogue scale (VAS) for pain (10 cm long line)
where zero represented no pain at all and 10 represented
the worst possible pain. Postoperatively, VAS-P was the cho-
sen method for assessment of pain severity. Upon arrival to
the operating room, standard monitors including non-invasive
blood pressure, electrocardiogram and pulse oximetry were
attached to the patient and baseline readings were collected.
An 18 gauge cannula was inserted in the dorsum of the left
hand and preload consisted of 10 ml/kg of lactated Ringer’s
solution before epidural insertion. Epidural catheter was in-
serted in the lumbar region at L4–L5 interspace under local
anesthesia and 3 ml lidocaine was given to all patients as an
epidural test dose. Then the patients were randomly allocated
into 4 equal groups 25 each by a closed envelope withdrawn
by the surgeon.
Group I (bupivacaine group): received 12 ml of the anes-
thetic admixture which included10 ml of bupivacaine
0.5% and 2 ml normal saline (N/S).
Group II (morphine group): received 12 ml of the anes-
thetic admixture which included 10 ml bupivacaine 0.5%
and 2 mg morphine sulfate in 2 ml normal saline.
Group III (morphine/neostigmine group): received 12 ml of
the anesthetic admixture which included 10 ml bupivacaine
0.5% and 1 ml N/S contained 2 mg morphine, 1 ml N/S
contained 5 lg/kg neostigmine (Neostigmine was provided
from the commercial solution of neostigmine methyl sulfate
(Epistigmine, 2.5 mg/mL; Epico, A.R.E).
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thetic admixture which included 10 ml bupivacaine 0.5%
and 2 ml containing 5 lg/kg neostigmine.
Incremental doses given to reach T6 sensory level (assessed
by pin brick) in all patients consisted of 3 ml of bupivacaine
0.5%. Plain bupivacaine 0.5% was infused epidurally to all pa-
tients after establishment of the level at a rate of 5 ml/h till the
end of surgery. Epidural catheters were removed immediately
after surgery. In order to keep the blind nature of the study,
the drugs were prepared in 20 ml syringes by a blind post-anes-
thesia care unit nurse according to the instructions written in a
closed envelope.
3. Data collected
1. Mean arterial blood pressure (MAP) and heart rate (HR)
were measured before insertion of epidural, 5 min after acti-
vation and every 15 min till the end of operation.
2. Incidence of urine retention and number of patients need-
ing urinary catheterization in each group. All patients were
instructed to void when feel desires or 4 h post operatively
when no desire felt, if patient failed to void we waited one
more hour. If no volitional voiding occurred and U/S
showed bladder volume 400 ml or more we proceeded for
urinary catheterization and urine volume was calculated.
3. Time to 1st rescue analgesic was recorded and 1 mg para-
cetamol intravenously was given when VASP 3. VAS
score was recorded every hour for the 1st 12 h by attending
nurse that was blind to the study group.
4. Incidence of complication (nausea, vomiting, pruritis,
hypotension, bradycardia and respiratory depression) in
each group and how it was managed. Respiratory depres-
sion was deﬁned as a respiratory rate <10 breath/min.
Bradycardia was deﬁned as heart rate less than 50 beats/
min. Hypotension was deﬁned as 20% decrease in mean
blood pressure below baseline levels and was managed by
ephedrine 9 mg intravenously that could be repeated if nec-
essary. Severe nausea or vomiting was treated with ondane-
setrone 4 mg while severe pruritis was treated with
chlorpheniramine maleate 10 mg IV slowly every 8 h as
required.
3.1. Statistical analysis
Obtained data were presented as means ± SD, ranges, num-
bers and ratios as appropriate. Categorical data were analyzed
using v2 test or Fischer exact test as appropriate. Continuous
data were analyzed using unpaired T-test or univariate two-
group repeated measures analysis of variance (ANOVA) withTable 1 Demographic data and patients characteristics.
Group I bupivacaine Group II morph
Age (year) 36(4) (27–45) 35(6) (23–47)
Body mass index (kg/m2) 26.3(2.6) (20–32) 25.4(2.8) (21–30
ASA physical status (I/II) 13/12 11/14
Duration of surgery (min) 97(7) (83–110) 99(6) (88–112)post hoc Dunnett as appropriate. Statistical calculations were
performed using SPSS (Version 10, 2002) for Windows statis-
tical package. P value <0.05 was considered statistically
signiﬁcant.
4. Results
The demographic data and patients characteristics of the four
groups are presented in Table 1 with no signiﬁcant differences
between the groups regarding age, body mass index, ASA
physical status, and duration of surgery Table 2.
Intraoperative hemodynamic data, heart rates and mean
blood pressures at regular intervals, were not statistically sig-
niﬁcantly different between the groups Tables 3–5.
Regarding urine retention, a single case occurred in the
bupivacaine group as the patient experienced sensation of full
bladder with inability to urinate 5 h after surgery and U/S
assessment revealed 600 ml urine in the bladder and the prob-
lem was solved by urinary catheterization to evacuate the blad-
der and did not recur again. In Group II ﬁve cases of retention
occurred, bladder volumes ranged between 480 and 950 ml,
patients started to experience difﬁculty in micturition from 5
to 11 h after surgery. The problem was solved by catheteriza-
tion once in four patients while the ﬁfth patient developed a
second attack of retention 6 h later solved by catheterization.
In Group III only one patient suffered from retention 5 h after
surgery and the residual volume was 850 ml urine. In Group
IV no single patient experienced retention. There was statisti-
cally signiﬁcant differences between Groups II and IV, P value
0.028 whereas no statistically signiﬁcant differences between
other groups.
Regarding postoperative nausea and vomiting, only one
case suffered from nausea in Group I and this occurred in
the recovery room immediately after the end of surgery and
was attributed to hypotension and corrected with I.V. injection
of 9 mg ephedrine sulfate and 4 mg ondanesetrone intrave-
nously and 200 ml infusion of ringer’s lactate over 5 min. In
Group II, ﬁve cases suffered from nausea and in a single case
the nausea was severe and proceeded into vomiting in the 24 h
following surgery. Meanwhile, three patients experienced nau-
sea in Group III and only one patient in Group IV and no
vomiting occurred in both groups. These cases were treated
with ondanesetrone 4 mg and dexamethasone 4 mg I.V.
Regarding pruritis one case occurred in both Groups II and
III. No pruritis was observed in the bupivacaine or neostig-
mine groups.
No respiratory depression was observed in any patient in
Groups I or IV, two cases in morphine group and one patient
inGroup IIIwasmanaged by supplemental oxygen through face
mask. Regarding bradycardia, one patient experienced brady-
cardia in Group II and another patient in Group III and the
bradycardia in those two patients was not associated withine Group III morphine/neostigmine Group IV neostigmine
37(4) (27–47) 35(5) (25–45)
) 25.6(2.6) (19–31) 27(3) (21–33)
10/15 11/14
95(7) (82–109) 93(8) (81–107)
Table 2 Preoperative urologic assessment.
Group I bupivacaine Group II morphine Group III morphine/neostigmine Group IV neostigmine
IPSS 1.28 (1.4) 1.12 (1.2) 1.36 (1.6) 1.08 (1.2)
Qmax (ml/s) 24.4 (4.3) 23.8 (4.2) 23.7 (3.8) 23.12 (3.4)
Post void residual urine (ml) 9.4 (7.2) 10.8 (7) 10.6 (7.3) 10 (7.7)
There was no statistically signiﬁcant difference between the four groups.
Intraoperative hemodynamic data, heart rates and mean blood pressures at regular intervals, were not statistically signiﬁcantly different between
the groups.
Table 3 Heart rate beat/min.
Heart rate beat/minute Group I bupivacaine Group II morphine Group III morphine/neostigmine Group IV neostigmine
Before Epidural insertion 81.05(11.9) 76.4(5.3) 77.5(10.8) 77.45(6.7)
5 min after 73.5(7.6) 72.1(6.5) 71.7(7.5) 72.1(7.6)
15 min 70.42(3.7) 72.65(6.9) 71.45(5.4) 71.25(5.6)
30 min 71.35(5.3) 70.25(5.7) 70.65(7.3) 72.45(5.9)
45 min 70.3(5.6) 71.2(8.2) 69.15(5.9) 69.65(5.8)
60 min 70.9(5.8) 70.4(8.8) 69.4(6.03) 69.15(6.1)
75 min 69.85(5.01) 70.3(7.5) 71.3(7.8) 71.0(7.7)
90 min 68.65(5.18) 69.9(4.66) 70.5(8.2) 70.85(8.08)
105 min 71.6(7.5) 68.45(5.88) 70.8(7.21) 70.6(7.8)
Table 4 Mean arterial blood pressure (mmHg).
Blood pressure mmHg Group I bupivacaine Group I morphine Group III morphine/neostigmine Group IV neostigmine
Before insertion 76.45(5.22) 77(5.35) 78.35(5.14) 77.5(5.53)
5 min after 73.55(5.44) 74.2(3.6) 75.25(5.36) 73.5(4.7)
15 min 73.65(3.55) 74.15(4.14) 75.6(4.56) 74.1(4.11)
30 min 74.7(3.04) 75.3(3.26) 75.05(4.34) 76.2(4.09)
45 min 75.35(4.98) 75.6(4.38) 76.05(4.93) 74.45(4.34)
60 min 75.75(4.21) 74.25(3.9) 75.1(3.16) 74.85(4.5)
75 min 75.56(2.5) 74.75(3.02) 74.6(2.8) 74.2(3.7)
90 min 74.5(5.6) 73.45(5.1) 73.9(6.64) 74.4(3.91)
105 min 73.9(6.03) 73.35(4.3) 74.1(7.03) 75.25(5.37)
Table 5 Incidence of postoperative complications.
Group I bupivacaine Group II morphine Group III morphine/neostigmine Group IV neostigmine P
Urine retention 1/25 5/25* 1/25 0/25* 0.028*
Pruritis 0/25 1/25 1/25 0/25 0.564 NS
PONV 1/25 5/25 3/25 1/25 0.180 NS
Respiratory depression 0/25 2/25 1/25 0/25 0.286 NS
Hypotension 1/25 1/25 1/25 1/25 1.000 NS
Bradycardia 0/25 1/25 1/25 0/25 0.564 NS
* Group II statistically signiﬁcant relative to Group IV.
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we did not use atropine. Regarding hypotension one patient in
each group suffered from hypotension and the condition
was managed with 9 mg ephedrine sulfate I.V. Table 6.
5. Discussion
Urine retention is a devastating problem commonly faced
with epidurally administered narcotic adjuvants especially
morphine [22]. Epidurally administered neostigmine has beenrecently used to prolong duration of analgesia and augment
the local anesthetic effects.
The main ﬁnding of our study was that the combined use of
neostigmine and morphine epidurally lessened the incidence of
urine retention faced when morphine is used alone and en-
hanced its analgesic effect. In the present study we tried to ex-
clude any factor that might precipitate any increase in the
incidence of urine retention aiming that our results to be a sole
reﬂection of the drugs administered. Our results showed that
only the patients that were assigned to neostigmine group
Table 6 Time for 1st rescue analgesic (min).
Group I bupivacaine Group II morphine Group III morphine/neostigmine Group IV neostigmine
Time in minutes 160(12) 710(63)b 824(41)a 524(39)c
There were statistically signiﬁcant differences between the four groups.
a Group III statistically signiﬁcant relative to the other three groups.
b Group II statistically signiﬁcant relative to the Groups I and IV.
c Group IV statistically signiﬁcant relative to Group I.
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addition of neostigmine minimized the incidence of POUR in
patients who received epidural morphine. To best of our
knowledge, although parenteral neostigmine has been used
as a rescue therapy for the treatment of POUR no previous
studies tested its effect when administered epidurally. Our re-
sults go with the result of Omais et al. [23], who studied the
side effects of epidural neostigmine and morphine and found
ﬁve patients in the morphine group who complained of urinary
retention out of ﬁfteen (incidence 33%) and three of them re-
quired a urinary catheter while in the morphine/neostigmine
group, two patients out of 15 (incidence 14%) complained of
urinary retention. Agarwal et al. [24] concluded that epidural
neostigmine is effective in providing analgesia and also it led
to the development of detrusor overactivity and decrease in
bladder capacity without any effect on voiding function so it
might help to avoid any voiding difﬁculty.
As noted from many previous studies, epidural analgesia in-
creases the incidence of postoperative urine retention. Walts et
al. [25] found an increase in the incidence of postoperative uri-
nary retention from 24% to 62%.with the use of epidural anal-
gesia in patients undergoing total hip arthroplasty. Moreover,
Gedney and Liu [6] studied the side effects of epidural opioids
and reported an incidence of 55% urine retention in patients
who underwent total joint arthroplasty. We could explain
the lower incidence of our study that ranged from 4% in
Groups I and III to 20% in Group II by the different selection
criteria of our patients, different age group (less than 50 years)
and also different type of surgery.
The analgesic efﬁcacy of epidural administered neostigmine
has been expressed by multiple authors. Some have found a
beneﬁcial effect, while others could not elucidate any effect.
Our results showed that neostigmine prolonged the time needed
for 1st rescue analgesic in neostigmine group relative to the
local anesthetic group and also the combined use of neostig-
mine with morphine prolonged that time statistically than mor-
phine alone. In line with our results was that of Nakayama et al.
[15] who found that neostigmine produced analgesia in a dose
dependant manner as 10 lg/kg neostigmine produced more
durable analgesia than 5 lg/kg in female patients who under-
went abdominal hysterectomies under epidural anesthesia.
Contrary to our results was that of Roelants et al. [26] who
demonstrated that epidural neostigmine given as a single dose
up to 4 lg/kg did not appear to provide an analgesic beneﬁt
during normal labor. However, this was explained by the fact
that labor pain was visceral in origin, while other studies
including ours were testing neostigmine in patients suffering
from somatic pain. More recently, Ross et al. [27] demon-
strated that epidural neostigmine up to 80 lg was effective in
labor pain as it reduced the epidural bupivacaine requirement
by 25% and lacked any signiﬁcant side effects upon mother or
fetus apart from mild sedation. Also Lauretti et al. [28], provedthat the addition of epidural neostigmine to lidocaine pro-
duced dose independent analgesia.
In the current study, the hemodynamic parameters (heart
rate and mean arterial blood pressure) did not vary among
the four groups throughout the study protocol. Consistent
with this view, Chung et al. [29], found that no signiﬁcant ad-
verse hemodynamic effects in maternity patients when neostig-
mine administered intrathecally during cesarean section. In
line with our results was that of Omais et al. [23], found that
the mean blood pressure and heart rate that were measured
at regular intervals were the same in all groups in their patients
receiving epidural morphine and neostigmine together with
spinal anesthesia for knee orthopedic surgery.
Our results showed that only one case in neostigmine group
suffered from nausea and vomiting postoperatively and this
goes in line with the results of Omais et al. [23] who found that
although PONV were very distressing side effects after intra-
thecal neostigmine, no adverse effects were noted after its epi-
dural administration. Moreover, Eisenach [30] reported that
the incidence of nausea and vomiting was very infrequent
and was not greater than that found in the control group. Also
our results showed that in the M/N group 3/25 suffered from
PONV while in the morphine group ﬁve patients suffered from
PONV. It also goes with the results of Roelants et al. [26] and
the results of Leuretti et al. [28] who found epidural adminis-
tration of neostigmine lacked these side effects. Therefore,
we suggest that those cases that experienced nausea and vom-
iting were mainly related to the use of epidural morphine.
Regarding pruritis, it occurred only in the two groups, M
and MN groups, where morphine was administered epidur-
ally and was not present in any patients in the other two
groups and also it was lower in the combined group. This
goes with the result of Ross et al. [27] who found that the
incidence of pruritus was signiﬁcantly lower in the mor-
phine/neostigmine group than in the morphine group. This
study needs to be conﬁrmed by other studies using larger
number of patients to support the accuracy of our hypothe-
sis. Conclusion: the use of epidural neostigmine is not asso-
ciated with urine retention; on the contrary it decreased the
incidence of urine retention faced with morphine and pro-
longed its analgesic effects.References
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